目的 研究止渴養(yǎng)陰膠囊聯(lián)合門冬胰島素治療2型糖尿病的臨床療效和安全性。方法 選取2013年2月-2015年10月于延安市人民醫(yī)院就診的2型糖尿病患者86例，隨機分成對照組和治療組，每組各43例。對照組皮下注射門冬胰島素注射液，起始劑量0.6 U/kg，每隔1～2天根據(jù)空腹血糖（FPG）和餐后2 h血糖（2 h PG）水平調(diào)整劑量。治療組在對照組的基礎(chǔ)上口服止渴養(yǎng)陰膠囊，3粒/次，3次/d。兩組患者均連續(xù)治療3個月。觀察兩組的臨床療效，同時比較兩組治療前后的FPG、2 h PG、HbAlc、空腹C肽、2 h C肽水平、血糖達標(biāo)時間、日血糖波動情況、日胰島素用量以及低血糖發(fā)生率。結(jié)果 治療后，對照組和治療組的總有效率分別為81.40%、95.35%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后FPG、2 h PG、HbAlc水平下降，空腹C肽水平升高，同組治療前后差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組FPG、2 h PG、HbAlc和空腹C肽水平改善程度優(yōu)于對照組，差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后治療組血糖達標(biāo)時間明顯縮短，日胰島素用量減少，低血糖發(fā)生率降低，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 止渴養(yǎng)陰膠囊聯(lián)合門冬胰島素能夠顯著的提高2型糖尿病的治療效果，減少日胰島素用量少，降低低血糖發(fā)生率。

Objective To study the clinical efficacies and safety of Zhike Yangyin Capsules combined with insulin aspart in treatment of type 2 diabetes. Methods Patients (86 cases) with type 2 diabetes in Yan'an People's Hospital from February 2013 to October 2015 were randomly divided into control group and treatment group, and each group had 43 cases. The patients in the control group were sc administered with Insulin Aspart Injection, the initial dosage was 0.6 U/kg, and the dosage was adjusted every 1-2 d according to FPG and 2 h PG levels. The patients in the treatment group were po administered with Zhike Yangyin Capsules on the basis of the control group, 3 grains/time, three times daily. The patients in two groups were treated for 3 months. After treatment, clinical efficacies were evaluated. And FPG, 2 h PG, HbAlc, fasting C-peptide, 2 h C-peptide, reaching target of glucose time, daily blood glucose fluctuation, daily insulin dosage, and hypoglycemia incidence in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.40% and 95.35%, respectively, and there were significant differences between two groups (P<0.05). After treatment, FPG, 2 h PG, and HbAlc levels in two groups were obviously decreased, and fasting C-peptide was obviously increased, the difference was statistically significant in the same group (P<0.05). These observational indexes in the treatment group were better than those in the control group, with significant difference between two groups (P<0.05). After treatment, reaching target of glucose time in the treatment group was significantly shortened, daily insulin dosage was reduced, and hypoglycemia incidence was decreased, with significant difference between two groups (P<0.05). Conclusion Zhike Yangyin Capsules combined with insulin aspart has a good clinical curative effect in treatment of type 2 diabetes, which can reduce daily insulin dosage and the incidence of hypoglycemia.